I appreciate the paper by Bolea-Alamanac et al. 1 on the use of methylphenidate in pregnancy and lactation. I would like to point the interested reader towards another recent review on this subject 2. We documented at least 180 first trimester exposed cases (excluding case stories and the case series referred to by Bolea-Alamanac et al. as this series was confounded by intravenous abuse of methylphenidate and concomitant use of pentazocine). We did not find that first trimester in utero exposure to methylphenidate was associated with an increased risk of congenital malformations.
Competing Interests
The author has completed the Unified Competing Interest form at http://www.icmje.org/coi_disclosure.pdf (available on request) and declares no support from any organization for the submitted work, no financial relationships with any organizations that might have an interest in the submitted work in the previous 3 years and no other relationships or activities that could appear to have influenced the submitted work.
References
- 1.Bolea-Alamanac BM, Green A, Verma G, Maxwell P, Davies SJ. Methylphenidate use in pregnancy and lactation, a systematic review of the evidence. Br J Clin Pharmacol. 2014;77:96–101. doi: 10.1111/bcp.12138. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Dideriksen D, Pottegård A, Hallas J, Aagaard L, Damkier P. First trimester in utero exposure to methylphenidate. Basic Clin Pharmacol Toxicol. 2013;112:73–76. doi: 10.1111/bcpt.12034. [DOI] [PubMed] [Google Scholar]